Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models
Open accessAbstract
In vitro cancer cell cultures are facile experimental models used widely for research and drug development. Many cancer cell lines are available and efforts are ongoing to derive new models representing the histopathological and molecular diversity of tumours. Cell models have been generated by multiple laboratories over decades and consequently their annotation is incomplete and inconsistent. Furthermore, the relationships between many patient-matched and derivative cell lines have been lost, and accessing information and datasets is time-consuming and difficult. Here, we describe the Cell Model Passports database; cellmodelpassports.sanger.ac.uk, which provides details of cell model relationships, patient and clinical information, as well as access to associated genetic and functional datasets. The Passports database currently contains curated details and standardized annotation for >1200 cell models, including cancer organoid cultures. The Passports will be updated with newly derived cell models and datasets as they are generated. Users can navigate the database via tissue, cancer-type, genetic feature and data availability to select a model most suitable for specific applications. A flexible REST-API provides programmatic data access and exploration. The Cell Model Passports are a valuable tool enabling access to high-dimensional genomic and phenotypic cancer cell model datasets empowering diverse research applications.
AI snapshot
Written from the paper’s full text.
TL;DR
Cell Model Passports is a database and web/API resource that curates >1200 cancer cell models, including organoids, with patient/sample/model relationships and links to genomic and drug sensitivity datasets. It aims to improve model selection, data integration, and reproducibility by standardizing annotation and identifiers.
Key findings
- The Passports database contains curated details and standardized annotation for >1200 cell models, including cancer organoid cultures; over 30 attributes may be annotated per model, with lineage captured via 29 tissue categories, 44 cancer types, and 194 cancer type detail categories.
- It provides >3500 genetic datasets and >1000 drug sensitivity datasets; 85% of cell models have associated somatic nucleotide variant, gene expression, copy number variation, or methylation datasets, and mutation status is provided for 455 cancer driver genes with drug profiling of ∼250 compounds from GDSC.
- The resource captures patient–sample–model hierarchies and parent–child model relationships, using unique identifiers such as RRID, COSMIC, and CCLE, and STR/fingerprinting to confirm model–patient associations and reduce mis-identification.
- Access is available through a web interface and a REST API following JSONAPI v1.0, with processed gene-level datasets and links to raw data.
Methods
- Database construction used PostgreSQL v9.6 hosted at the Wellcome Sanger Institute; the REST API was developed in Python 3.6 with Flask v0.12 and SQLAlchemy v1.2, and the web interface used React v16.4 with Bootstrap v4.0.
- Curation compiled information from commercial cell banks (ATCC, DSMZ, JCRB, ECACC), academic collaborators, Cellosaurus, CCLE, and publications; a constrained vocabulary was developed, and the patient/sample/model hierarchy was established using annotation plus resources cataloging mis-identified and synonymous models, with STR/fingerprinting to confirm associations.
- The foundational model set includes >1200 established cancer cell lines and newly derived organoid models, including those used in the Sanger GDSC project and models from the Human Cancer Models Initiative; genomic features include microsatellite stability status, ploidy, mutational burden, and mutation status of 455 cancer driver genes.
Limitations
- The paper states that currently all datasets have been generated by the Sanger Institute, and that the Passports currently focus on high quality and consistent datasets generated by the Wellcome Sanger Institute; future expansion to external resources is planned.
- The paper states that the Passports will incorporate newly generated datasets from initiatives such as the Dependency Map at Sanger, indicating that some relevant datasets are not yet included.
- Evident from the text: no formal user evaluation, benchmarking, or performance assessment of the web interface or API is reported; the paper is primarily descriptive of the resource.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
0 of 32 cited sources checked · 0 supported · 0 flagged
- Findingnone given
Users can navigate the Passports database via tissue, cancer-type, genetic feature and data availability to select a model suitable for specific applications.
“Users can navigate the database via tissue, cancer-type, genetic feature and data availability to select a model most suitable for specific applications.”
Quote in the paperSubstantial claim - Findingnone given
The Cell Model Passports is a central portal providing manual or programmatic access to a cancer cell model database containing curated patient, sample and model relationship information as well as genomic and functional datasets.
“The Cell Model Passports is a central portal providing manual or programmatic access to a cancer cell model database containing curated patient, sample and model relationship information as well as genomic and functional datasets.”
Quote in the paperSubstantial claim - Findingown data
The Passports database currently contains curated details and standardized annotation for more than 1200 cell models, including cancer organoid cultures.
“The Passports database currently contains curated details and standardized annotation for >1200 cell models, including cancer organoid cultures.”
- Also stated in: § MODEL ANNOTATIONS · plain
“More than 1200 established cancer cell lines and newly derived organoid models comprise the foundational model set of the Passports, including all those utilized in the Sanger’s GDSC project (5, 18) as well as cell models generated as part of the Human Cancer Models Initiative.”
Quote in the paperSubstantial claim - Also stated in: § MODEL ANNOTATIONS · plain
- Findingcitation
The Passport model name is accompanied by synonyms and unique identifiers utilized by established resources such as RRID, COSMIC and CCLE to aid data integration and alignment.
“The Passport model name is accompanied by synonyms and most importantly unique identifiers utilized by established resources such as Research Resource Identifiers (RRID) (19), the Catalogue of Somatic Mutations in Cancer (COSMIC) (20) and CCLE (6) to aid data integration and alignment.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [19] Bairoch, 2018, The Cellosaurus, a Cell-Line Knowledge Resource, J. Biomol. Tech. source
Not checked in the free run.
- cites [20] Forbes, 2017, COSMIC: somatic cancer genetics at high-resolution, Nucleic Acids Res. source
Not checked in the free run.
- cites [6] Barretina, 2012, The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature source
Not checked in the free run.
- Findingnone given
The Passports currently focus on high quality and consistent datasets generated by the Wellcome Sanger Institute.
“The Passports currently focus on high quality and consistent datasets generated by the Wellcome Sanger Institute, but in the future will expand to include cell models and datasets generated by external resources while maintaining an emphasis on quality and curation.”
Quote in the paperNot a substantial claim
- Findingcitation
Annotation of genomic features has been provided for each model via the exploitation of the available genomic datasets, including microsatellite stability status, ploidy, mutational burden and the mutation status of 455 cancer driver genes.
“Annotation of genomic features has been provided for each model via the exploitation of the available genomic datasets. Features include microsatellite stability status, ploidy, mutational burden and the mutation status of 455 cancer driver genes (18).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [18] Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell source
Not checked in the free run.
- Findingnone given
All genes with an HGNC-approved symbol as of April 2018 are currently included in the Passports, including those without a protein product.
“All genes with an HGNC-approved symbol as of April 2018 are currently included in the Passports, including those without a protein product.”
Quote in the paperNot a substantial claim - Findingnone given
Model lineage is provided through three progressively granular fields: 'Tissue' (n = 29 categories), 'Cancer Type' (n = 44) and 'Cancer Type Detail' (n = 194).
“Model lineage, a requirement for tissue-specific analyses, is provided through three progressively granular fields: ‘Tissue’ (n = 29 categories), ‘Cancer Type’ (n = 44) and ‘Cancer Type Detail’ (n = 194).”
Quote in the paperNot a substantial claim - Findingown data
Most cell models (85%) have associated somatic nucleotide variant, gene expression, copy number variation or methylation datasets.
“Most cell models (85%) have associated somatic nucleotide variant, gene expression, copy number variation or methylation datasets (Figure 2 and Supplementary Table S2).”
Quote in the paperSubstantial claim - Findingown data
Over 30 attributes may be annotated to a model including primary name, synonyms, tissue of origin, disease details including treatment, and patient information such as gender, ethnicity and age.
“Over 30 attributes may be annotated to a model including primary name, synonyms, tissue of origin, disease details including treatment as well as patient information, such as gender, ethnicity and age (Supplementary Table S1).”
Quote in the paperNot a substantial claim - Findingcitation
Top drug sensitivities for cell models are provided as determined by the drug profiling of ∼250 compounds as part of the GDSC project.
“Furthermore, top drug sensitivities for cell models are also provided as determined by the drug profiling of ∼250 compounds as part of the GDSC project (18).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [18] Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell source
Not checked in the free run.
- Findingnone given
All genes have been assigned an internal ID, allowing mapping to current and previous HGNC gene symbols, Ensembl Gene IDs (v91) and other external gene identifiers.
“All genes have been assigned an internal ID, allowing mapping to current and previous HGNC gene symbols, Ensembl Gene IDs (v91) and other external gene identifiers.”
Quote in the paperNot a substantial claim - Premisecitation
The length of time in culture, culture conditions and exogenous selective pressures on a cell line can lead to genetic drift.
“The length of time in culture, culture conditions and exogenous selective pressures on a cell line (e.g. PDX engraftment) can lead to genetic drift (16, 17).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [16] Behrens, 2003, Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers?, Eur. J. Pharm. Sci. source
Not checked in the free run.
- cites [17] Ben-David, 2018, Genetic and transcriptional evolution alters cancer cell line drug response, Nature source
Not checked in the free run.
- Interpretationreasoning
Informed selection of cancer models based on patient, clinical and molecular features, and the availability of associated datasets, is currently time consuming and difficult.
“As a result of these issues, the informed selection of cancer models based on patient, clinical and molecular features, and the availability of associated datasets is currently time consuming and difficult.”
Quote in the paperSubstantial claim- Rests on an assumption: Datasets associated with cell models are often inaccessible to non-computational, wet-lab scientists.
- Rests on an assumption: It is often difficult to determine what information is available for a particular cell line and how to access these data.
- Study design and conductcitation
STR/fingerprinting profiles gathered internally and during curation were analysed to confirm model-patient associations.
“In addition STR/fingerprinting profiles gathered internally and during curation were analysed to confirm model-patient associations (33, 34).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [33] Capes-Davis, 2010, Check your cultures! A list of cross-contaminated or misidentified cell lines, Int. J. Cancer source
Not checked in the free run.
- cites [34] Masters, 2001, Short tandem repeat profiling provides an international reference standard for human cell lines, Proc. Natl. Acad. Sci. U.S.A. source
Not checked in the free run.
- Interpretationreasoning
To the best of our knowledge, there are no other web-resources providing a centralized portal with cell model relationship information, access to associated datasets and annotation of cancer gene status and drug sensitivity.
“To the best of our knowledge, there are no other web-resources providing a centralized portal with cell model relationship information, access to associated datasets and annotation of cancer gene status and drug sensitivity.”
Quote in the paperSubstantial claim - Premisecitation
cBioPortal and COSMIC are primarily focused on patient tumour genomic data.
“Second, cBioPortal and COSMIC are primarily focused on patient tumour genomic data.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [36] Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov. source
Not checked in the free run.
- cites [20] Forbes, 2017, COSMIC: somatic cancer genetics at high-resolution, Nucleic Acids Res. source
Not checked in the free run.
- Premisereasoning
Neither cBioPortal, PharmacoDB nor COSMIC curate samples to map unique identifiers or link samples and models from the same patient, which can be important for identifying mis-identified or cross-contaminated samples.
“Third, neither cBioPortal, PharmacoDB nor COSMIC curate samples to map unique identifiers or link samples and models from the same patient, which can be important for identifying mis-identified or cross-contaminated samples.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [36] Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov. source
Not checked in the free run.
- cites [35] Smirnov, 2018, PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies, Nucleic Acids Res. source
Not checked in the free run.
- cites [20] Forbes, 2017, COSMIC: somatic cancer genetics at high-resolution, Nucleic Acids Res. source
Not checked in the free run.
- Interpretationreasoning
The Cell Model Passport database builds upon and extends the functionality of existing resources.
“Thus, the Cell Model Passport database builds upon and extends the functionality of existing resources.”
Quote in the paperSubstantial claim
- May combine two claims. 20
- Classified as probably not a substantial claim. 15
May combine two claims.
FindingcitationMore than 1200 established cancer cell lines and newly derived organoid models comprise the foundational model set of the Passports, including all those utilized in the Sanger's GDSC project and cell models generated as part of the Human Cancer Models Initiative.
“More than 1200 established cancer cell lines and newly derived organoid models comprise the foundational model set of the Passports, including all those utilized in the Sanger’s GDSC project (5, 18) as well as cell models generated as part of the Human Cancer Models Initiative.”
Quote in the paperSubstantial claim0 of 2 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
Findingnone givenA flexible REST-API provides programmatic data access and exploration.
“A flexible REST-API provides programmatic data access and exploration.”
- Also stated in: § API · plain
“Programmatic access to the Cell Model Passports database is available through a flexible API.”
Quote in the paperNot a substantial claim- Also stated in: § API · plain
May combine two claims.
Findingown dataThe Cell Model Passports database provides details of cell model relationships, patient and clinical information, and access to associated genetic and functional datasets.
“Here, we describe the Cell Model Passports database; cellmodelpassports.sanger.ac.uk, which provides details of cell model relationships, patient and clinical information, as well as access to associated genetic and functional datasets.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingnone givenAll relationships between resources are fully annotated within the API, including API URLs to related resources.
“To facilitate access to available resources, all relationships between resources are fully annotated within the API, including API URLs to related resources.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingown dataOver 3500 genetic datasets and more than 1000 drug sensitivity datasets are available in the Passports.
“Over 3500 genetic datasets and more than 1000 drug sensitivity datasets are available.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenAny dataset values that were mapped to genes without an official gene symbol have been discarded from processing, but continue to be available in raw data downloads.
“Any dataset values that were mapped to genes without an official gene symbol have been discarded from processing, but continue to be available in raw data downloads.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
FindingreasoningThe website enables users to search and/or filter for cell models via a variety of features as well as providing access to datasets.
“The website enables users to search and/or filter for cell models via a variety of features as well as providing access to datasets.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenCancer driver mutation status for a model is provided as a word cloud, where text size represents the prevalence of mutations in a gene for all cell models of the same tissue type, and the colour differentiates between tumour suppressors and oncogenes.
“Cancer driver mutation status for a model is provided as a word cloud, where text size represents the prevalence of mutations in a gene for all cell models of the same tissue type, and the colour differentiates between tumour suppressors and oncogenes.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenThe search and filter functions allow users to conduct direct queries for an individual model or cancer and combine filters to identify a cohort of cell models with a particular set of characteristics.
“The search and filter functions allow users to not only conduct direct queries for an individual model or cancer, but also combine filters to identify a cohort of cell models with a particular set of characteristics.”
Quote in the paperNot a substantial claimMay combine two claims.
Findingnone givenModels in the Passports have been derived from primary, metastatic, pre-cancerous and normal samples as indicated by 'Tissue Status', and the anatomical site from which the sample was obtained 'Sample Site' is also provided.
“Models in the Passports have been derived from primary, metastatic, pre-cancerous and normal samples as indicated by ‘Tissue Status’, the anatomical site from which the sample was obtained ‘Sample Site’ is also provided.”
Quote in the paperNot a substantial claimMay combine two claims.
FindingreasoningThe Cell Model Passport is a centralized cell model hub, providing a platform for researchers to investigate key patient and sample information, manually and programmatically access multiple genetic and functional datasets, and facilitate integration of data from different sources through mapping of unique identifiers.
“The Cell Model Passport is a centralized cell model hub, providing a platform for researchers to investigate key patient and sample information, manually and programmatically access multiple genetic and functional datasets, and facilitate integration of data from different sources through mapping of unique identifiers.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenMultiple information panels are displayed on the Model Page; 'Model Information' is provided for all models while additional panels are dependent upon availability of relevant information.
“Multiple information panels are displayed on the Model Page (Figure 3). ‘Model Information’ is provided for all models while additional panels are dependent upon availability of relevant information.”
Quote in the paperNot a substantial claimMay combine two claims.
FindingreasoningProcessed datasets provide gene-level information, rather than segment or transcript, allowing direct integration and cross-comparisons with other datasets within the Passports.
“The processed datasets provide gene-level information, rather than segment or transcript, allowing direct integration and cross-comparisons with other datasets within the Passports.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).
Findingnone givenThe processed files and a description of cancer driver gene status for each model facilitates access for non-informaticians.
“The processed files and a description of cancer driver gene status for each model facilitates access for non-informaticians.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenData files are hosted on a robust S3 object store platform or in third party repositories; the Cell Model Passport database contains links to these files together with associated metadata.
“Data files are hosted on a robust S3 object store platform or in third party repositories; the Cell Model Passport database contains links to these files together with associated metadata.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingnone givenEndpoints are available for lists of patients, samples, models, identifiers, files, all processed datasets and cancer driver mutations.
“Endpoints are available for lists of patients, samples, models, identifiers, files, all processed datasets and cancer driver mutations.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingnone givenDrug sensitivity data obtained from the GDSC project are reported showing the compounds to which a model is most sensitive.
“Drug sensitivity data obtained from the GDSC project are also reported showing the compounds to which a model is most sensitive.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Findingnone givenThere are two categories of files, each with their own database table: generic files and model files.
“There are two categories of files, each with their own database table: generic files and model files.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe lack of a consistent controlled vocabulary to describe cell line metadata and the large number of synonymous identifiers makes data integration and cross-referencing of datasets burdensome.
“The lack of a consistent controlled vocabulary to describe cell line metadata and the large number of synonymous identifiers makes data integration and cross-referencing of datasets burdensome (14, 15).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
PremisecitationKey patient and clinical information, including relationships between cell lines originally derived from the same patient or sample, has been lost.
“In addition, key patient and clinical information has been lost including relationships between cell lines originally derived from the same patient or sample (13).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [13] Vermeulen, 1998, Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient, Cancer Genet. Cytogenet. source
Not checked in the free run.
May combine two claims.
PremisecitationMany cancer cell models have been cross-contaminated or are associated with numerous synonymous identifiers.
“Many models have inadvertently been cross-contaminated (9–11) or are associated with numerous synonymous identifiers (11, 12).”
Quote in the paperSubstantial claim0 of 4 sources checked- cites [9] Gartler, 1968, Apparent Hela cell contamination of human heteroploid cell lines, Nature source
Not checked in the free run.
- cites [10] Nelson-Rees, 1974, Banded marker chromosomes as indicators of intraspecies cellular contamination, Science source
Not checked in the free run.
- cites [11] Lorsch, 2014, Cell Biology. Fixing problems with cell lines, Science source
Not checked in the free run.
- cites [12] Luong, 2011, A call for standardized naming and reporting of human ESC and iPSC lines, Cell Stem Cell source
Not checked in the free run.
Probably not a substantial claim: may not pass S2 (checkable).
InterpretationreasoningA clear understanding of the characteristics and source of the model used to generate a given dataset is important for reproducibility of results.
“Therefore, a clear understanding of the characteristics and source of the model used to generate a given dataset is important for reproducibility of results.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Study design and conductreasoningBy default, models sharing common ancestry are assigned to separate samples of a single patient, unless evidence is available indicating otherwise; this conservative approach ensures data can be accurately attributed to the specific cell model, thereby improving reproducibility between users of the same or related models.
“By default, models sharing common ancestry are assigned to separate samples of a single patient, unless evidence is available indicating otherwise. This relatively conservative approach ensures data can be accurately attributed to the specific cell model, thereby improving reproducibility between users of the same or related models.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationCellosaurus and cBioPortal do not provide cell model functional information, while PharmacoDB does not contain genomic annotation of the cell models and has limited sample/model information.
“First, Cellosaurus and cBioPortal do not provide cell model functional information, while PharmacoDB does not contain genomic annotation of the cell models and has limited sample/model information.”
Quote in the paperSubstantial claim0 of 3 sources checked- cites [19] Bairoch, 2018, The Cellosaurus, a Cell-Line Knowledge Resource, J. Biomol. Tech. source
Not checked in the free run.
- cites [35] Smirnov, 2018, PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies, Nucleic Acids Res. source
Not checked in the free run.
- cites [36] Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov. source
Not checked in the free run.
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationRecent technological advancements (e.g. organoid models and conditionally reprogrammed cell lines) have led to a new generation of cancer cell models being derived to allow full representation of the histopathological and molecular diversity of tumours.
“Furthermore, with recent technological advancements (e.g. organoid models and conditionally reprogrammed cell lines), a new generation of cancer cell models is being derived to allow full representation of the histopathological and molecular diversity of tumours (37–42).”
Quote in the paperNot a substantial claim0 of 6 sources checked- cites [37] van de Wetering, 2015, Prospective derivation of a living organoid biobank of colorectal cancer patients, Cell source
Not checked in the free run.
- cites [38] Broutier, 2017, Human primary liver cancer-derived organoid cultures for disease modeling and drug screening, Nat. Med. source
Not checked in the free run.
- cites [39] Sachs, 2018, A living biobank of breast cancer organoids captures disease heterogeneity, Cell source
Not checked in the free run.
- cites [40] Tiriac, 2018, Organoid profiling identifies common responders to chemotherapy in pancreatic cancer, Cancer Discov. source
Not checked in the free run.
- cites [41] Boj, 2015, Organoid models of human and mouse ductal pancreatic cancer, Cell source
Not checked in the free run.
- cites [42] Nanki, 2018, Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis, Cell source
Not checked in the free run.
May combine two claims.
Study design and conductreasoningCurrently, all datasets in the Passports have been generated by the Sanger Institute, and consequently there is a direct relationship between the cell model described and the datasets provided, mitigating the risk of mis-identification and genetic drift.
“Currently, all datasets have been generated by the Sanger Institute and consequently there is a direct relationship between the cell model described and the datasets provided, mitigating the risk of mis-identification and genetic drift.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThe Cell Model Passports provide a resource to reduce the mis-identification of cell models, facilitate data integration and subsequently improve experimental reproducibility in cancer research and related fields.
“In summary, the Cell Model Passports provide a resource to reduce the mis-identification of cell models, facilitate data integration and subsequently improve experimental reproducibility in cancer research and related fields.”
Quote in the paperSubstantial claim
The paper relies on this without support.
Datasets associated with cell models are often inaccessible to non-computational, wet-lab scientists.
“Furthermore, these datasets are often inaccessible to non-computational, wet-lab scientists.”
The paper relies on this without support.
It is often difficult to determine what information is available for a particular cell line and how to access these data.
“Although many cell lines have been genetically and functionally characterized, it is often difficult to determine what information is available for a particular cell line and how to access these data.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fitness Scores calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines represent a quantitative measure of the reduction of cell viability elicited by gene inactivation via CRISPR/Cas9.
“''Fitness Scores'' that were calculated from large-scale genome-wide CRISPR/Cas9 screens across 31 independent CRC cell lines and represent a quantitative measure of the reduction of cell viability elicited by a gene inactivation via CRISPR/Cas9 (https://score.depmap.sanger.ac.uk) (Behan et al., 2019;van der Meer et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as van der Meer et al., 2019
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · see citing works
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · see citing works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381 · see citing works
Alley, M. C., Scudiero, D. A., Monks, A. P., Hursey, M. L., Czerwiński, M., Fine, D. L., Abbott, B. J., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988) · PubMed · Cited by 3,082 · see citing works
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456 · see citing works
Self-citationProspective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408 · see citing works
Self-citationGiard, D. J., Aaronson, S. A., Todaro, G. J., Arnstein, P., Kersey, J. H., Dosik, H., & Parks, W. P. (1973) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/51.5.1417 · Cited by 2,293 · see citing works
Organoid models of human and mouse ductal pancreatic cancer
Boj, S. F., Hwang, C.-I., Baker, L. A., Chio, I. I. C., Engle, D. D., Corbo, V., Jager, M., Ponz-Sarvise, M., Tiriac, H., Spector, M. S., et al. (2015) · Cell · doi:10.1016/j.cell.2014.12.021 · Cited by 2,150 · see citing works
A Landscape of Pharmacogenomic Interactions in Cancer
Iorio, F., Knijnenburg, T. A., Vis, D. J., Bignell, G. R., Menden, M. P., Schubert, M., Aben, N., Gonçalves, E., Barthorpe, S., Lightfoot, H., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.017 · Cited by 2,090 · see citing works
Self-citationA living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973 · see citing works
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922 · see citing works
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · see citing works
Self-citationOrganoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer
Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092 · see citing works
Genetic and transcriptional evolution alters cancer cell line drug response
Ben-David, U., Siranosian, B., Ha, G., Tang, H., Oren, Y., Hinohara, K., Strathdee, C. A., Dempster, J., Lyons, N. J., Burns, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0409-3 · Cited by 931 · see citing works
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813 · see citing works
The Cellosaurus, a Cell-Line Knowledge Resource
Bairoch, A. (2018) · Journal of Biomolecular Techniques JBT · doi:10.7171/jbt.18-2902-002 · Cited by 807 · see citing works
Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization
Cailleau, R., Olivé, M., & Cruciger, Q. V. J. (1978) · In Vitro · doi:10.1007/bf02616120 · Cited by 679 · see citing works
Check your cultures! A list of cross‐contaminated or misidentified cell lines
Capes‐Davis, A., Theodosopoulos, G., Atkin, I., Drexler, H. G., Kohara, A., MacLeod, R. A. F., Masters, J. R., Nakamura, Y., Reid, Y. A., Reddel, R. R., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25242 · Cited by 520 · cited 3× · see citing works
“In addition STR / fingerprinting profiles gathered internally and during curation were analysed to confirm model-patient associations (33, 34).”
BackgroundMethodShort tandem repeat profiling provides an international reference standard for human cell lines
Masters, J. R., Thomson, J. A., Daly-Burns, B., Reid, Y. A., Dirks, W. G., Packer, P., Toji, L. H., Ohno, T., Tanabe, H., Arlett, C. F., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121616198 · Cited by 478 · see citing works
Divergent Routes toward Wnt and R-spondin Niche Independency during Human Gastric Carcinogenesis
Nanki, K., Toshimitsu, K., Takano, A., Fujii, M., Shimokawa, M., Ohta, Y., Matano, M., Seino, T., Nishikori, S., Ishikawa, K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.027 · Cited by 335 · see citing works
NCI-navy medical oncology branch cell line data base
Phelps, R. M., Johnson, B. E., Ihde, D. C., Gazdar, A. F., Carbone, D. P., McClintock, P. R., Linnoila, R. I., Matthews, M. J., Bunn, P. A., Carney, D. N., et al. (1996) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240630505 · Cited by 304 · see citing works
Turc‐Carel, C., Philip, I., Berger, M. S., Philip, T. O., & Lenoir, G. (1984) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(84)90002-5 · Cited by 288 · see citing works
A resource for cell line authentication, annotation and quality control
Yu, M., Selvaraj, S. K., Liang-Chu, M. M. Y., Aghajani, S., Busse, M., Yuan, J., Lee, G., Peale, F., Klijn, C., Bourgon, R., et al. (2015) · Nature · doi:10.1038/nature14397 · Cited by 243 · cited 2× · see citing works
“The lack of a consistent controlled vocabulary to describe cell line metadata and the large number of synonymous identifiers makes data integration and cross-referencing of datasets burdensome (14, 15).”
BackgroundApparent HeLa Cell Contamination of Human Heteroploid Cell Lines
GARTLER, S. M. (1968) · Nature · doi:10.1038/217750a0 · Cited by 226 · see citing works
Banded Marker Chromosomes as Indicators of Intraspecies Cellular Contamination
Nelson-Rees, W. A., Flandermeyer, R. R., & Hawthorne, P. K. (1974) · Science · doi:10.1126/science.184.4141.1093 · Cited by 210 · see citing works
Characteristics of cell lines established from human colorectal carcinoma.
Park, J. G., Oie, H. K., Sugarbaker, P. H., Henslee, J. G., Chen, T. R., Johnson, B. E., & Gazdar, A. F. (1987) · PubMed · Cited by 202 · see citing works
False leukemia–lymphoma cell lines: an update on over 500 cell lines
Drexler, H. G., Dirks, W. G., Matsuo, Y., & MacLeod, R. A. F. (2003) · Leukemia · doi:10.1038/sj.leu.2402799 · Cited by 202 · see citing works
Fixing problems with cell lines
Lorsch, J. R., Collins, F. S., & Lippincott-Schwartz, J. (2014) · Science · doi:10.1126/science.1259110 · Cited by 179 · see citing works
PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies
Smirnov, P., Kofia, V., Maru, A., Freeman, M., Ho, C., El-Hachem, N., Adam, G.-A., Ba-alawi, W., Safikhani, Z., & Haibe-Kains, B. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx911 · Cited by 155 · see citing works
Wong, M. P., Cheung, N., Yuen, S. T., Leung, S. Y., & Chung, L. P. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990611)81:6 · Cited by 123 · see citing works
Behrens, I., & Kissel, T. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(03)00146-5 · Cited by 117 · see citing works
Establishment and characterisation of six human biliary tract cancer cell lines
Ku, J.-L., Yoon, K.-A., Kim, I., Kim, W. H., Jang, J.-Y., Suh, K.-S., Kim, S.-W., Park, Y., Hwang, J.-H., Yoon, Y.-B., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600440 · Cited by 88 · see citing works
DNA fingerprinting of glioma cell lines and considerations on similarity measurements
Bady, P., Diserens, A.-C., Castella, V., Kalt, S., Heinimann, K., Hamou, M.-F., Delorenzi, M., & Hegi, M. E. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos072 · Cited by 57 · see citing works
Korch, C., Hall, E. M., Dirks, W. G., Ewing, M., Faries, M., Varella‐Garcia, M., Robinson, S., Storts, D., Turner, J. A., Wang, Y., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31067 · Cited by 53 · see citing works
A call for standardized naming and reporting of human ESC and iPSC lines.
Luong, M. X., Auerbach, J., Crook, J. M., Daheron, L., Hei, D., Lomax, G., Loring, J. F., Ludwig, T., Schlaeger, T. M., Smith, K. P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.03.002 · Cited by 53 · see citing works
Vermeulen, S. J. T., Chen, T. R., Speleman, F., Nollet, F., Roy, F. M. V., & Mareel, M. M. K. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00081-8 · Cited by 46 · see citing works
A Standard Nomenclature for Referencing and Authentication of Pluripotent Stem Cells
Kurtz, A., Seltmann, S., Bairoch, A., Bittner, M.-S., Bruce, K., Capes-Davis, A., Clarke, L., Crook, J. M., Daheron, L., Dewender, J., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.002 · Cited by 46 · see citing works
Establishment and characterization of human laryngeal squamous cell carcinoma cell lines
Ku, J., Kim, W., Lee, J., Park, H., Kim, K. H., Sung, M., & Park, J. (1999) · The Laryngoscope · doi:10.1097/00005537-199906000-00025 · Cited by 20 · see citing works
The Mass Production and Distribution of HeLa Cells at Tuskegee Institute, 1953–55
BROWN, R. W., & Henderson, J. H. (1983) · Journal of the History of Medicine and Allied Sciences · doi:10.1093/jhmas/38.4.415 · Cited by 17 · see citing works
Yuan, Y., Kim, W. H., Han, H. S., Lee, J., Park, H., Chung, J.-K., Kang, S., & Park, J. (1997) · Gynecologic Oncology · doi:10.1006/gyno.1997.4802 · Cited by 12 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1103-9 · Cited by 1,338 · see citing works
Self-citationEffective drug combinations in breast, colon and pancreatic cancer cells
Jaaks, P., Coker, E. A., Vis, D. J., Edwards, O., Carpenter, E. F., Leto, S. M., Dwane, L., Sassi, F., Lightfoot, H., Barthorpe, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04437-2 · Cited by 469 · see citing works
Self-citationCancer Cell Lines Are Useful Model Systems for Medical Research
Mirabelli, P., Coppola, L., & Salvatore, M. (2019) · Cancers · doi:10.3390/cancers11081098 · Cited by 346 · see citing works
Integrated cross-study datasets of genetic dependencies in cancer
Pacini, C., Dempster, J. M., Boyle, I. A., Gonçalves, E., Najgebauer, H., Karakoç, E., van der Meer, D., Barthorpe, A. S., Lightfoot, H., Jaaks, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-021-21898-7 · Cited by 294 · see citing works
Self-citationDrugComb: an integrative cancer drug combination data portal
Zagidullin, B., Aldahdooh, J., Zheng, S., Wang, W., Wang, Y., Saad, J. J., Malyutina, A., Jafari, M., Tanoli, Z., Pessia, A., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz337 · Cited by 265 · see citing works
Pan-cancer proteomic map of 949 human cell lines
Gonçalves, E., Poulos, R. C., Cai, Z., Barthorpe, S., Manda, S. S., Lucas, N., Beck, A., Bucio-Noble, D., Dausmann, M., Hall, C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.010 · Cited by 228 · see citing works
Self-citationArtificial intelligence, machine learning, and drug repurposing in cancer
Tanoli, Z., Vähä-Koskela, M. J. V., & Aittokallio, T. A. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1883585 · Cited by 224 · see citing works
Phenotypic plasticity and genetic control in colorectal cancer evolution
Househam, J., Heide, T., Cresswell, G. D., Spiteri, I., Kimberley, C., Zapata, L., Lynn, C., James, C. T., Mossner, M., Fernández-Mateos, J., et al. (2022) · Nature · doi:10.1038/s41586-022-05311-x · Cited by 181 · see citing works
Picco, G., Chen, E. D., García‐Alonso, L., Behan, F. M., Gonçalves, E., Bignell, G. R., Matchan, A., Fu, B., Banerjee, R., Anderson, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09940-1 · Cited by 128 · see citing works
Self-citationDrugComb update: a more comprehensive drug sensitivity data repository and analysis portal
Zheng, S., Aldahdooh, J., Shadbahr, T., Wang, Y., Aldahdooh, D., Bao, J., Wang, W., & Tang, J. P. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab438 · Cited by 128 · see citing works
Dwane, L., Behan, F. M., Gonçalves, E., Lightfoot, H. W., Yang, W., van der Meer, D. J., Shepherd, R., Pignatelli, M., Iorio, F., & Garnett, M. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa882 · Cited by 119 · see citing works
Self-citationPicco, G., Cattaneo, C. M., van Vliet, E. J., Crisafulli, G., Rospo, G., Consonni, S., Vieira, S. F., Sánchez-Rodríguez, I., Cancelliere, C., Banerjee, R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1508 · Cited by 112 · see citing works
Self-citationPacini, C., Duncan, E., Gonçalves, E., Gilbert, J. G. R., Bhosle, S. G., Horswell, S. D., Karakoç, E., Lightfoot, H. W., Curry, E. W., Muyas, F., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.016 · Cited by 107 · see citing works
Self-citationDrug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
Gonçalves, E., Segura‐Cabrera, A., Pacini, C., Picco, G., Behan, F. M., Jaaks, P., Coker, E. A., van der Meer, D., Barthorpe, A. S., Lightfoot, H. W., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199405 · Cited by 103 · see citing works
Self-citationDegradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95 · see citing works
Base editing screens map mutations affecting interferon-γ signaling in cancer
Coelho, M. A., Cooper, S., Strauß, M. E., Karakoç, E., Bhosle, S. G., Gonçalves, E., Picco, G., Burgold, T., Cattaneo, C. M., Veninga, V., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.009 · Cited by 93 · see citing works
Self-citationNovel WRN Helicase Inhibitors Selectively Target Microsatellite-Unstable Cancer Cells
Picco, G., Rao, Y., Saedi, A. A., Lee, Y., Vieira, S. F., Bhosle, S. G., May, K., Herranz, C., Walker, S. J., Shenje≠, R., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0052 · Cited by 68 · see citing works
Self-citationBase editing screens define the genetic landscape of cancer drug resistance mechanisms
Coelho, M. A., Strauß, M. E., Watterson, A., Cooper, S., Bhosle, S. G., Illuzzi, G., Karakoç, E., Dinçer, C., Vieira, S. F., Sharma, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01948-8 · Cited by 64 · see citing works
Self-citationAtlas of Lobular Breast Cancer Models: Challenges and Strategic Directions
Sflomos, G., Schipper, K., Koorman, T., Fitzpatrick, A., Oesterreich, S., Lee, A. V., Jonkers, J., Brunton, V. G., Christgen, M., Isacke, C. M., et al. (2021) · Cancers · doi:10.3390/cancers13215396 · Cited by 51 · see citing works
Seo, H., Tkachuk, D., Ho, C., Mammoliti, A., Rezaie, A., Tonekaboni, S. A. M., & Haibe‐Kains, B. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa421 · Cited by 50 · see citing works
Lord, C. J., Quinn, N., & Ryan, C. J. (2020) · eLife · doi:10.7554/elife.58925 · Cited by 44 · see citing works
The 26th annual Nucleic Acids Research database issue and Molecular Biology Database Collection
Rigden, D. J., & Fernández, X. M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1267 · Cited by 48 · see citing works
A suspension technique for efficient large-scale cancer organoid culturing and perturbation screens
Price, S., Bhosle, S. G., Gonçalves, E., Li, X., McClurg, D. P., Barthorpe, S., Beck, A., Hall, C., Lightfoot, H. W., Farrow, L., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09508-y · Cited by 46 · see citing works
Self-citationZhou, Y., Dai, Q., Xu, Y., Wu, S., Cheng, M., & Zhao, B. T. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01082-6 · Cited by 48 · see citing works
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Bashi, A. C., Coker, E. A., Bulusu, K. C., Jaaks, P., Crafter, C., Lightfoot, H. W., Milo, M., McCarten, K., Jenkins, D. F., van der Meer, D. J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0388 · Cited by 43 · see citing works
Self-citationDrug-adapted cancer cell lines as preclinical models of acquired resistance
Michaelis, M., Wass, M. N., & Cinatl, J. J. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.005 · Cited by 43 · see citing works
CELLector: Genomics-Guided Selection of Cancer In Vitro Models
Najgebauer, H., Yang, M., Francies, H. E., Pacini, C., Stronach, E. A., Garnett, M. J., Sáez-Rodríguez, J., & Iorio, F. (2020) · Cell Systems · doi:10.1016/j.cels.2020.04.007 · Cited by 43 · see citing works
Self-citationSynthetic augmentation of cancer cell line multi-omic datasets using unsupervised deep learning
Cai, Z., Apolinário, S., Baião, A. R., Pacini, C., Sousa, M. D., Vinga, S., Reddel, R. R., Robinson, P. J., Garnett, M. J., Zhong, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54771-4 · Cited by 44 · see citing works
Self-citationBéal, J., Pantolini, L., Noël, V., Barillot, E., & Calzone, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007900 · Cited by 42 · see citing works
A systematic evaluation of deep learning methods for the prediction of drug synergy in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010200 · Cited by 38 · see citing works
Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies
Salvati, A., Melone, V., Giordano, A., Lamberti, J., Palumbo, D., Palo, L., Rea, D., Memoli, D., Simonis, V., Alexandrova, E., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06856-x · Cited by 40 · see citing works
Lenoir, W. F., Morgado, M. C., DeWeirdt, P. C., McLaughlin, M. E., Griffith, A. L., Sangree, A. K., Feeley, M. N., Anvar, N. E., Kim, E., Bertolet, L. L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26867-8 · Cited by 29 · see citing works
Wang, X., Zhu, H., Chen, D., Yu, Y., Liu, Q., & Liu, Q. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad351 · Cited by 32 · see citing works
Computational estimation of quality and clinical relevance of cancer cell lines
Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31 · see citing works
Mooney, B., Negri, G. L., Shyp, T., Delaidelli, A., Zhang, H., Miko, S. E. S., Weiner, A. K., Radaoui, A. B., Shraim, R., Lizardo, M. M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2187 · Cited by 30 · see citing works
Baird, L., & Yamamoto, M. P. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102904 · Cited by 30 · see citing works
Page, C. L., Amuzu, S., Rahimi, K., Gotlieb, W. H., Ragoussis, J., & Tonin, P. N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.005 · Cited by 30 · see citing works
Mechanism of activation and the rewired network: New drug design concepts
Nussinov, R., Zhang, M., Maloney, R., Tsai, C., Yavuz, B. R., Tunçbağ, N., & Jang, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21863 · Cited by 30 · see citing works
Kurz, C. G., Preuß, F., Tjaden, A., Cusack, M., Amrhein, J. A., Chatterjee, D., Mathea, S., Berger, L. M., Berger, B., Krämer, A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00173 · Cited by 30 · see citing works
Optimization of Cas12a for multiplexed genome-scale transcriptional activation
Griffith, A. L., Zheng, F., McGee, A. V., Miller, N., Szegletes, Z. M., Reint, G., Gademann, F., Nwolah, I., Hegde, M., Liu, Y. V., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100387 · Cited by 26 · see citing works
A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles
Sinha, R., Luna, A., Schultz, N. D., & Sander, C. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100039 · Cited by 28 · see citing works
Looking at the BiG picture: incorporating bipartite graphs in drug response prediction
Hostallero, D. E., Li, Y., & Emad, A. (2022) · Bioinformatics · doi:10.1093/bioinformatics/btac383 · Cited by 28 · see citing works
Ancestry matters: Building inclusivity into preclinical study design
Zaaijer, S., & Capes‐Davis, A. (2021) · Cell · doi:10.1016/j.cell.2021.03.041 · Cited by 27 · see citing works
Vinceti, A., Karakoç, E., Pacini, C., Perron, U., Lucia, R. R. D., Garnett, M. J., & Iorio, F. (2021) · BMC Genomics · doi:10.1186/s12864-021-08129-5 · Cited by 27 · see citing works
Self-citationCEN‐tools: an integrative platform to identify the contexts of essential genes
Sharma, S., Dinçer, C., Weidemüller, P., Wright, G. J., & Petsalaki, E. (2020) · Molecular Systems Biology · doi:10.15252/msb.20209698 · Cited by 25 · see citing works
PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
Zhang, L., Hsu, J. I., & Goodell, M. A. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-1018 · Cited by 26 · see citing works
Novel NRF2 ‐activated cancer treatments utilizing synthetic lethality
Baird, L., Kensler, T. W., & Yamamoto, M. P. (2022) · IUBMB Life · doi:10.1002/iub.2680 · Cited by 26 · see citing works
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
Bhin, J., Yemelyanenko, J., Chao, X., Klarenbeek, S., Opdam, M., Malka, Y., Hoekman, L., Kruger, D. T., Bleijerveld, O. B., Brambillasca, C. S., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20211743 · Cited by 26 · see citing works
Grillone, K., Ascrizzi, S., Cremaschi, P., Amato, J., Polerà, N., Croci, O., Rocca, R., Riillo, C., Conforti, F., Graziano, R., et al. (2024) · Blood · doi:10.1182/blood.2023021991 · Cited by 23 · see citing works
Pan-cancer clinical impact of latent drivers from double mutations
Yavuz, B. R., Tsai, C., Nussinov, R., & Tunçbağ, N. (2023) · Communications Biology · doi:10.1038/s42003-023-04519-5 · Cited by 25 · see citing works
RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity
Angioni, R., Bonfanti, M., Caporale, N., Sánchez‐Rodríguez, R., Munari, F., Savino, A., Pasqualato, S., Buratto, D., Pagani, I., Bertoldi, N., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101266 · Cited by 22 · see citing works
Szalai, B., & Veres, D. V. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1126044 · Cited by 21 · see citing works
Kim, N., Hwang, C. Y., Kim, T., Kim, H., & Cho, K. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-1559 · Cited by 21 · see citing works
Functional genomics approaches to improve pre‐clinical drug screening and biomarker discovery
Nguyen, L. V., & Caldas, C. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013189 · Cited by 17 · see citing works
Dinçer, C., Kaya, T., Keskin, Ö., Gürsoy, A., & Tunçbağ, N. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006789 · Cited by 19 · see citing works
Zhou, Y., Sun, Y., Huang, D., & Li, M. J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00053 · Cited by 19 · see citing works
Absolute copy number fitting from shallow whole genome sequencing dataPreprint
Sauer, C. M., Eldridge, M., Vias, M., Hall, J. A. M., Boyle, S. E., Macintyre, G., Bradley, T. P., Markowetz, F. M., & Brenton, J. D. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.19.452658 · Cited by 17 · see citing works
Defining the landscape of metabolic dysregulations in cancer metastasis
Kader, S. A., Dib, S. S., Achkar, I. W., Thareja, G., Suhre, K., Rafii, A., & Halama, A. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10140-9 · Cited by 18 · see citing works
Park, B., Raha, P., Pankovich, J., & Bazett, M. (2022) · Cancers · doi:10.3390/cancers15010028 · Cited by 18 · see citing works
Predicting anticancer synergistic drug combinations based on multi-task learning
Chen, D., Wang, X., Zhu, H., Jiang, Y., Li, Y., Liu, Q., & Liu, Q. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05524-5 · Cited by 18 · see citing works
From organoids to bedside: Advances in modeling, decoding and targeting of colorectal cancer
Betge, J., & Jackstadt, R. (2022) · International Journal of Cancer · doi:10.1002/ijc.34297 · Cited by 16 · see citing works
CREAMMIST: an integrative probabilistic database for cancer drug response prediction
Yingtaweesittikul, H., Wu, J., Mongia, A., Peres, R., Ko, K. K. K., Nagarajan, N., & Suphavilai, C. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac911 · Cited by 18 · see citing works
Chen, X., Qian, W., Song, Z., Li, Q.-X., & Guo, S. (2020) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqaa060 · Cited by 19 · see citing works
Perron, U., Grassi, E., Chatzipli, A., Viviani, M., Karakoç, E., Trastulla, L., Brochier, L. M., Isella, C., Zanella, E. R., Klett, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53163-y · Cited by 17 · see citing works
Jaiswal, A., Gautam, P., Pietilä, E. A., Timonen, S., Nordström, N., Akimov, Y. A., Sipari, N., Tanoli, Z., Fleischer, T., Lehti, K., et al. (2021) · Molecular Systems Biology · doi:10.15252/msb.20209526 · Cited by 15 · see citing works
Kimmel, G. J., Dane, M. A., Heiser, L. M., Altrock, P. M., & Andor, N. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1231 · Cited by 15 · see citing works
IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth
Jing, X., Han, C., Li, Q., Li, F., Zhang, J., Jiang, Q., Zhao, F., Guo, C., Chen, J., Jiang, T., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119542 · Cited by 15 · see citing works
PDCM Finder: an open global research platform for patient-derived cancer models
Perova, Z., Martinez, M., Mandloi, T., López, F., Halmagyi, C., Follette, A., Mason, J., Newhauser, S., Begley, D. A., Krupke, D. M., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1021 · Cited by 15 · see citing works
Scalable and universal prediction of cellular phenotypes enables in silico experimentsPreprint
Ji, Y., Tejada-Lapuerta, A., Schmacke, N. A., Zheng, Z., Zhang, X., Khan, S., Rothenaigner, I., Tschuck, J., Hadian, K., Hornung, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.12.607533 · Cited by 15 · see citing works
PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma
Liu, X.-L., Zhang, G., Huang, S., Shi, W.-H., Ye, L.-X., Ren, Z., Zhang, J., Liu, S., Yu, L., & Li, Y.-L. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00862-1 · Cited by 14 · see citing works
Haplotype-specific assembly of shattered chromosomes in esophageal adenocarcinomas
Ijaz, J., Harry, E. F., Raine, K. M., Menzies, A. H., Beal, K. M., Quail, M. A., Zumalave, S., Jung, H., Coorens, T. H. H., Lawson, A. R. J., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2023.100484 · Cited by 14 · see citing works
Self-citationOhnmacht, A. J., Rajamani, A., Avar, G., Kutkaite, G., Gonçalves, E., Saur, D., & Menden, M. P. (2023) · Communications Biology · doi:10.1038/s42003-023-05198-y · Cited by 13 · see citing works
The LL-100 Cell Lines Panel: Tool for Molecular Leukemia–Lymphoma Research
Drexler, H. G., & Quentmeier, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165800 · Cited by 14 · see citing works
Advancing CRISPR with deep learning: A comprehensive review of models and databases
Alipanahi, R., Safari, L., & Khanteymoori, A. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102691 · Cited by 14 · see citing works
Circadian transcriptome of pancreatic adenocarcinoma unravels chronotherapeutic targets
Sharma, D., Adnan, D., Abdel-Reheem, M. K., Anafi, R. C., Leary, D. D., & Bishehsari, F. (2024) · JCI Insight · doi:10.1172/jci.insight.177697 · Cited by 12 · see citing works
M3NetFlow: A multi-scale multi-hop graph AI model for integrative multi-omic data analysis
Zhang, H., Goedegebuure, S. P., Ding, L., DeNardo, D., Fields, R. C., Province, M., Chen, Y., Payne, P., & Li, F. (2025) · iScience · doi:10.1016/j.isci.2025.111920 · Cited by 12 · see citing works
Vis, D. J., Jaaks, P., Aben, N., Coker, E. A., Barthorpe, S., Beck, A., Hall, C., Hall, J. A. M., Lightfoot, H. W., Lleshi, E., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101687 · Cited by 11 · see citing works
Self-citationKleandrova, V. V., Cordeiro, M. N. D. S., & Speck‐Planche, A. (2024) · Applied Sciences · doi:10.3390/app14209344 · Cited by 11 · see citing works
Normalization Strategies for Lipidome Data in Cell Line Panels
Leegwater, H., Zhang, Z., Zhang, X., Hankemeier, T., Harms, A. C., Zweemer, A. J. M., Dévédec, S. E. L., & Kindt, A. S. D. (2024) · Journal of Chemometrics · doi:10.1002/cem.3636 · Cited by 10 · see citing works
Prognostic Significance of Dysregulated Epigenomic and Chromatin Modifiers in Cervical Cancer
Paul, A. M., Pillai, M. R., & Kumar, R. (2021) · Cells · doi:10.3390/cells10102665 · Cited by 10 · see citing works
Voutsadakis, I. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020411 · Cited by 10 · see citing works
Highlights from the 1st European cancer dependency map symposium and workshop
Trastulla, L., Savino, A., Beltrão, P., Cortés‐Ciriano, I., Fenici, P., Garnett, M. J., Guerini, I., Bigas, N. L., Mattaj, I. W., Petsalaki, E., et al. (2023) · FEBS Letters · doi:10.1002/1873-3468.14699 · Cited by 9 · see citing works
Self-citationBayó, C., Castellano, G., Marín, F., Castillo‐Iturra, J., Ocaña, T., Kumari, H., Pellisé, M., Moreira, L., Rivero, L., Daca-Álvarez, M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011177 · Cited by 8 · see citing works
Fischer, P., Schmid, M., Ohradanova‐Repic, A., Schneeweiss, R., Hadatsch, J., Grünert, O., Benedum, J., Rohrer, A. M., Staudinger, F., Schatzlmaier, P., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07873-w · Cited by 11 · see citing works
A tumour-derived organoid biobank maps cancer gene dependencies
Herranz‐Ors, C., Bhosle, S. G., Beck, A. E., Gilbert, J. G. R., Picco, G., Valle-Inclán, J. E., Muyas, F., Valentini, S., Andres, A. E., Ansari, R., et al. (2026) · Nature · doi:10.1038/s41586-026-10830-y · Cited by 10 · see citing works
Self-citationVoutsadakis, I. A. (2022) · Medicina · doi:10.3390/medicina58101498 · Cited by 8 · see citing works
Using DeepSignalingFlow to mine signaling flows interpreting mechanism of synergy of cocktails
Zhang, H., Chen, Y., Payne, P., & Li, F. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00421-w · Cited by 8 · see citing works
In Silico Prediction of Tumor Neoantigens with TIminer
Kirchmair, A., & Finotello, F. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0327-7_9 · Cited by 8 · see citing works
Cell line models for drug discovery in PIK3CA-mutated colorectal cancers
Voutsadakis, I. A. (2022) · Medical Oncology · doi:10.1007/s12032-022-01695-y · Cited by 8 · see citing works
Üstünel, Ş., Sternbach, S., Prévôt, M. E., Freeman, E. J., McDonough, J. A., Clements, R. J., & Hegmann, E. (2023) · Journal of Applied Polymer Science · doi:10.1002/app.53883 · Cited by 8 · see citing works
Pettirossi, V., Venanzi, A., Rosseto, A. S., Schiavoni, G., Santi, A., Tasselli, L., Naccari, M., Pensato, V., Pucciarini, A., Martelli, M. P., et al. (2023) · Leukemia · doi:10.1038/s41375-022-01788-7 · Cited by 7 · see citing works
Liu, Y., Zhao, M., & Qu, H. (2023) · Biology · doi:10.3390/biology12030357 · Cited by 7 · see citing works
Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
Sharma, S., & Wright, G. J. (2020) · Journal of Visualized Experiments · doi:10.3791/60803 · Cited by 7 · see citing works
Cellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer Therapeutics
George, B., Pillai, P. M., Paul, A. M., Revikumar, A., Leitzel, K. E., Ali, S. M., Sandiford, O. A., Lipton, A., Rameshwar, P., Hortobágyi, G. N., et al. (2021) · Cells · doi:10.3390/cells10020433 · Cited by 7 · see citing works
Gao, F., Hu, K., Zheng, P., Shi, H., & Ke, X. (2023) · Cancer Medicine · doi:10.1002/cam4.5756 · Cited by 6 · see citing works
Multiaction Pt(IV) Complexes: Cytotoxicity in Ovarian Cancer Cell Lines and Mechanistic Studies
Tabrizi, L., Jones, A. M., Romero‐Canelón, I., & Erxleben, A. (2024) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c01586 · Cited by 6 · see citing works
Cell Surface Receptor Identification Using Genome-Scale CRISPR/Cas9 Genetic Screens
Sharma, S., & Wright, G. J. (2020) · Journal of Visualized Experiments · doi:10.3791/60803-v · Cited by 6 · see citing works
Park, T. Y., Leiserson, M. D. M., Klau, G. W., & Raphael, B. J. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100099 · Cited by 6 · see citing works
Effectively utilizing publicly available databases for cancer target evaluation
Croft, D. R., Lodhia, P., Lourenco, S. D. S., & MacKay, C. (2023) · NAR Cancer · doi:10.1093/narcan/zcad035 · Cited by 6 · see citing works
The EFFECT benchmark suite: measuring cancer sensitivity prediction performance - without the bias
Szalai, B., Gáspár, I., Kaszás, V., Mérő, L., Sztilkovics, M., & Szalay, K. Z. (2023) · doi:10.1101/2023.10.02.560281 · Cited by 5 · see citing works
- Authors
- van der Meer, D., Barthorpe, S., Yang, W., Lightfoot, H., Hall, C., Gilbert, J., Francies, H. E., & Garnett, M. J.
- Affiliations
- Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, CB10 1SA, UK
- Wellcome Sanger Institute (GB)
- Corresponding author
- Francies, Hayley E
- Garnett, Mathew J
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-09-27
- Volume
- 47
- Issue
- D1
- Pages
- D923-D929
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC6324059
- OpenAlex
- W2893209354
- Semantic Scholar
- a3d79f0a93ca5e44a28c400635b41f824442ac63
- Cited by
- 195
- References
- 42
- Citations by year
- 2026: 21 · 2025: 32 · 2024: 27 · 2023: 35 · 2022: 22 · 2021: 31 · 2020: 17 · 2019: 8 · 2018: 1
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Cancer Research UK (C44943/A22536)
- Stand Up To Cancer (SU2C-AACRDT1213)
- Wellcome Trust (102696)
- Wellcome Sanger Institute (206194)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Physical Sciences › Computer Science › Information Systems › Research Data Management Practices
- Keywords
- cancer cell lines, preclinical cancer models, tumor organoids, REST API, database curation, drug development models
- MeSH terms
- Drug Development, Antineoplastic Agents, Humans, Models, Biological, Organoids, Databases, Factual, Genomics, Cell Line, Tumor, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-10.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-10.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review